High-flow nasal cannula oxygen in children with bronchiolitis: A randomized controlled trial

Area of Science:

• Pediatrics
• Respiratory Medicine
• Critical Care

Background:

• Bronchiolitis is a common respiratory infection in infants, often requiring oxygen therapy.
• Current treatments include low-flow oxygen (LFO), but enhanced respiratory support options are being explored.

Purpose of the Study:

• To compare the efficacy of high-flow nasal cannula oxygen (HFNCO) versus LFO in providing respiratory support for infants with moderate-to-severe bronchiolitis.

Main Methods:

• A prospective, randomized controlled trial involving 87 children aged 1-24 months with moderate-to-severe bronchiolitis.
• Participants received either LFO (6-10 L/min) or HFNCO (2 L/kg/min).
• Primary outcomes included time to normalization of heart rate (HR), respiratory rate (RR), and clinical respiratory score (CRS).

Main Results:

• HFNCO therapy resulted in significantly shorter times for HR and RR normalization (2.0h vs. 12.0h for HR; 4.0h vs. 24.0h for RR) and CRS improvement (2.0h vs. 4.0h) compared to LFO.
• Duration of oxygen requirement and treatment failure rates were significantly lower in the HFNCO group (19.0h vs. 29.5h; 3% vs. 21%).
• No significant differences were observed in length of stay or adverse events between the groups.

Conclusions:

• HFNCO offers enhanced respiratory support for infants with bronchiolitis, leading to quicker physiological improvements and reduced treatment failure compared to LFO.
• Further comprehensive studies are warranted to fully assess the clinical efficacy of HFNCO therapy in this population.